Equities

Celldex Therapeutics Inc

Celldex Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)26.22
  • Today's Change-0.25 / -0.94%
  • Shares traded1.28m
  • 1 Year change-1.06%
  • Beta1.5645
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Celldex Therapeutics Inc had net income fall 25.91% from a loss of 112.33m to a larger loss of 141.43m despite a 192.02% increase in revenues from 2.36m to 6.88m.
Gross margin--
Net profit margin-1,544.48%
Operating margin-1,871.27%
Return on assets-27.93%
Return on equity-29.84%
Return on investment-29.53%
More ▼

Cash flow in USDView more

In 2023, Celldex Therapeutics Inc increased its cash reserves by 18.30%, or 5.39m. Cash Flow from Financing totalled 218.46m or 3,173.88% of revenues. In addition the company used 107.29m for operations while cash used for investing totalled 105.78m.
Cash flow per share-2.48
Price/Cash flow per share--
Book value per share11.85
Tangible book value per share11.44
More ▼

Balance sheet in USDView more

Celldex Therapeutics Inc uses little or no debt in its capital structure.
Current ratio24.27
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.